Understanding Myomo's Upcoming Earnings Release
Myomo (AMEX: MYO) is gearing up to announce its quarterly earnings soon. Investors are advised to tune in as the company reveals key financial data that could influence its stock's trajectory. With a projected earnings per share (EPS) of $-0.11, the anticipation surrounding Myomo's performance is palpable.
The market's eyes are on Myomo, with high hopes that the earnings report will exceed expectations and provide optimistic guidance for the upcoming quarter. Effective guidance can heavily impact stock prices, making it crucial for both new and seasoned investors to grasp these insights.
Analyzing Myomo's Historical Earnings Performance
Last quarter, Myomo experienced a miss in EPS by $0.00, leading to an immediate 38.64% drop in its share price the following trading day. This shift illustrates the importance of aligning actual results with market expectations.
Reviewing Myomo's recent earnings history can reveal patterns regarding stock reactions post-announcement:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.11 | -0.08 | -0.02 | -0.04 |
| EPS Actual | -0.11 | -0.08 | -0.01 | -0.03 |
| Price Change % | -39.00 | -31.00 | 41.00 | 20.00 |
Evaluating Myomo's Stock Performance
As of the last trading day, Myomo's shares were valued at $0.817. Over the past year, the stock has seen a considerable decline of 83.16%. This downturn could understandably leave long-term investors feeling uncertain about the future, especially with the earnings announcement approaching.
Connecting with Analysts' Perspectives
For investors, understanding market sentiments is essential. Currently, Myomo holds two analyst ratings, with the consensus leaning towards a Buy, and an impressive average one-year price target of $7.75. This outlook suggests a promising potential upside of 848.59%.
Comparing Peer Ratings
Analyzing peers such as NeuroOne Medical Tech, Femasys, and Co-Diagnostics provides additional context for evaluating Myomo's relative standing.
- NeuroOne Medical Tech is given a Buy recommendation, with an average target of $3.00 indicating a potential upside of 267.2%.
- Femasys also garners a Buy rating, with a target of $8.00 showing a possible upside of 879.19%.
- Co-Diagnostics, similarly rated Buy, has a one-year price target of $5.80, anticipating a 609.91% upside.
Insights from Peer Analysis
The comparative analysis sheds light on key metrics that define each company's performance against Myomo. These insights can aid investors in assessing overall market dynamics.
| Company | Consensus | Revenue Growth | Gross Profit | Return on Equity |
|---|---|---|---|---|
| Myomo | Buy | 28.34% | $6.05M | -23.57% |
| NeuroOne Medical Tech | Buy | 105.39% | $914.84K | -32.27% |
| Femasys | Buy | 84.78% | $251.10K | -261.74% |
| Co-Diagnostics | Buy | -93.87% | $130.80K | -17.36% |
Key Takeaway: Myomo excels in terms of revenue growth and gross profit when compared to its peers. Notably, it ranks lower in its Return on Equity, indicating a need for improvement in this regard.
Exploring Myomo's Core Business
Myomo Inc is a trailblazing company in the realm of wearable medical robotics, known for designing and producing myoelectric orthotics aimed at aiding those with neuromuscular disorders. The MyoPro device is a registered Class II medical device that the company markets directly to patients while working closely with insurance providers.
Analyzing Myomo's Financial Health
Market Capitalization Insight: Myomo's market cap reflects its size constraints, shaped by various factors including growth potential and operational capabilities.
Impressive Revenue Growth: Myomo reported a noteworthy revenue growth rate of 28.34% as of the latest quarter, which places it ahead of many competitors in the Health Care sector.
Effective Cost Management: The company maintains a commendable net margin of -47.99%, illustrating sound financial practices.
Strong Return on Equity: Myomo exhibits a return on equity of -23.57%, showcasing competent use of equity in their operations.
Asset Utilization: With a return on assets of -11.65%, Myomo demonstrates effective asset management.
Debt Management Strategy: Myomo’s debt-to-equity ratio stands at 0.71, indicating a robust financial structure.
Frequently Asked Questions
What is Myomo's projected earnings per share (EPS)?
Myomo's projected EPS for the upcoming earnings report is $-0.11.
How did Myomo's stock perform in the past year?
In the last 52 weeks, Myomo's shares have decreased by 83.16%.
What do analysts think about Myomo's stock?
Analysts have an overall Buy consensus for Myomo, with a potential upside of 848.59% based on the average one-year price target.
What is Myomo’s revenue growth rate?
Myomo has achieved a revenue growth rate of 28.34% over the recent quarter.
What are Myomo's competitive strengths?
Myomo stands out for its revenue growth and gross profit, although it needs improvement in Return on Equity.
